 Camrelizumab plus chemotherapy versus chemoradiotherapy as neoadjuvant therapy for resectable esophageal squamous cell carcinoma: Phase 2 randomized trial (REVO)Peiyuan Wang,
Yujie Chen,
Feng Wang,
Mingqiu Chen,
Buhong Zheng,
Derong Zhang,
Qingfeng Zheng,
Jiezhong Wang,
Junqiang Chen,
Huaxin Cai,
Junhua Liu,
Wenshan Zhang,
Changhong Lian,
Juhui Chen,
Yu Lin,
Yuanji Xu,
Rongfang Huang,
Mengxia Lei,
Peng Chen,
Hao He,
Hui Lin,
Xiaofeng Chen,
Hang Zhou,
Weijie Chen,
Wenwei Wei,
Fengnian Zhuang,
Junpeng Lin,
Canhua Huang,
Ni Guan,
Jin Yan,
Shujun Liang,
Shuoyan Liu () and
Jiancheng Li ()
Nature Communications, 2025, vol. 16, issue 1, 1-8 Abstract: Abstract Several studies have evaluated PD-1 inhibitors plus chemotherapy as neoadjuvant treatment for locally advanced esophageal squamous cell carcinoma (ESCC), but comparative data with chemoradiotherapy (CRT) remain limited. This multicenter, randomized, open-label, phase 2 non-inferiority trial (REVO, NCT05007145) assessed the efficacy and safety of neoadjuvant camrelizumab plus chemotherapy (ICT) versus CRT in patients with resectable, locally advanced ESCC. A total of 104 patients were randomized to ICT (camrelizumab, nab-paclitaxel, cisplatin) or CRT (nab-paclitaxel, cisplatin, radiotherapy). The primary endpoint was pathologic complete response (pCR). ICT achieved a pCR rate of 32.7% versus 34.6% with CRT (rate ratio 0.94, 90% CI 0.6–1.49), demonstrating non-inferiority and meeting the pre-specified primary endpoint. Major pathologic response was observed in 42.3% of ICT patients and 57.7% of CRT patients, with R0 resection achieved in 100% of both groups. 1-year disease-free survival was 89.1% versus 78.2%, and 1-year overall survival was 100% versus 92.3% for ICT and CRT, respectively. Grade ≥3 treatment-related adverse events occurred in 19.2% of ICT patients and 33.3% of CRT patients, and surgical complications were reported in 31.1% and 35.9%, respectively. These findings indicate that ICT is a safe and effective neoadjuvant strategy for resectable ESCC with a more favorable safety profile. Date: 2025 Downloads: (external link) Related works: Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:16:y:2025:i:1:d:10.1038_s41467-025-64660-z Ordering information: This journal article can be ordered from DOI: 10.1038/s41467-025-64660-z Access Statistics for this article Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie More articles in Nature Communications from Nature |
Is your work missing from RePEc? Here is how to contribute.
Questions or problems? Check the EconPapers FAQ or send mail to .
EconPapers is hosted by the
School of Business at Örebro University.